Cellectis S.A. · EURONEXT:ALCLS

Cellectis — Investor Presentation (January 2022)

27 slides from Cellectis's investor presentation, January 2022

  1. Slide 1: Corporate Presentation January 2022

    Commitment to a Cure Corporate Presentation January 2022 NASDAQ: CLLS EURONEXT GROWTH: ALCLS.PA

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains “forward-looking” statements within These forward-looking statements are made in light of the meaning of applicable securities laws, including the Private information currently available to us and are subject to Securities Litigation Reform Act o

  3. Slide 3: Mission Statement

    Mission Statement CELLECTIS IS A CLINICAL-STAGE BIOTECH USING ITS PIONEERING GENE-EDITING PLATFORM TO DEVELOP LIFE-SAVING CELL AND GENE THERAPIES 3

  4. Slide 4: Key Highlights

    Key Highlights 3 ongoing clinical trials • 30+ patients dosed in Cellectis-sponsored trials 140+ patients dosed • In 5 trials sponsored by Cellectis’ licensed partners $201M GMP facilities Meaningful Milestones operational since Expected Over the Next 12 Cash runway mid-2021 Months into 2024 • End-t

  5. Slide 5: Allogeneic CAR-T Cell Pipeline

    Allogeneic CAR-T Cell Pipeline Phase 1 Dose Phase 1 Dose Pivotal Product Disease Study Preclinical Escalation Expansion Phase2 Upcoming Expected Milestones Acute Lymphoblastic DL3 with FCA preconditioning UCART22 BALLI-01 Leukemia Start dosing in-house products Acute Myeloid DL2 and DL2i with FCA UC

  6. Slide 6: Diversified Partnerships with Industry Leaders

    Diversified Partnerships with Industry Leaders Exclusive worldwide license to CD19- 2014 Up To $410M In Development & Sales directed allogeneic CAR T-cells CAR-T Milestones U.S. Rights Sublicensed to Allogene CD19 + Low Double-Digit Royalties on Sales 20151 by Servier CAR-T Up To $2.8B In Developmen

  7. Slide 7: Powerful and Comprehensive Gene Editing Platform

    Powerful and Comprehensive Gene Editing Platform Gene Knockout Gene Repair Gene Replacement Gene Insertion Nucleases Experts in Gene Editing: Self-owned ü 30+ years for Cellectis’ founders electroporation technology ü 22 years doing gene editing Base editors ü 10 years developing TALEN® Gene Knockou

  8. Slide 8: Why TALEN®?

    Why TALEN®? SAFE Avoids unintended genetic modifications EFFICIENT High rates of gene editing for Knock Outs and Knock Ins PRECISE Targets editing at the desired site (up to the base pair) Strong IP 8

  9. Slide 9: Why TALEN®? TALEN vs CRISPR

    Why TALEN®? TALEN® CRISPR PRECISION Every 7 base pairs > Every 64 base pairs ACTIVITY KO, balanced KI > KO, unbalanced KI Euchromatin, GENOME OUTREACH heterochromatin >> Euchromatin only CUTTING FEATURES Centered > Distal RECOGNITION SITE 32 base pairs >> ~20 base pairs SAFETY No chemotrypsis detect

  10. Slide 10: Our Focus in 2022

    Our Focus in 2022 Generate clinical data from our 3 ongoing trials To support determination of recommended phase 2 dose (RP2D) and lymphodepletion for: • UCART22 in r/r B-ALL patients • UCART123 in r/r AML patients • UCARTCS1 in r/r MM patients File IND & Initiate Phase 1 for • UCART20x22 in r/r NHL

  11. Slide 11: Cellectis Allogeneic CAR-T Cell Programs: UCART Platform

    Cellectis Allogeneic CAR-T Cell Programs UCART Platform 11

  12. Slide 12: Allogeneic CAR-T cell Therapies are the Future

    Allogeneic CAR-T cell Therapies are the Future Scalable manufacturing “Off-the-shelf” availability Reduced cost: Immediately available to 1 batch = 100s doses ❶ ❷ patients Cancer Allogeneic Treatment UCART Decision Therapy Efficiency & robustness Market access Potency and consistency Available to al

  13. Slide 13: Cellectis' Clinical-Stage Candidate UCART Products

    Cellectis’ Clinical-Stage Candidate UCART Products TALEN® Powered Targeting CD123 CAR123 For AML TCRα KO Against GvHD Targeting CD22 CD52 KO CAR22 Resistance to alemtuzumab For ALL OR CS1 KO Targeting CS1/SLAMF7 Self-lymphodepleting CD52 or CS1 CARCS1 For MM 13

  14. Slide 14: UCART22 – BALLI-01 Trial Design

    UCART22 – BALLI-01 Trial Design Open Label Dose-escalation And Dose-expansion Study To Evaluate The Safety, Expansion, Persistence And Clinical Activity Of UCART22 In Patients With Relapsed Or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia Determine MTD Dose Expansion Dose Escalation and/or RP

  15. Slide 15: UCART22 Administration Demonstrated a Tolerable Safety Profile

    UCART22 Administration Demonstrated a Tolerable Safety Profile PATIENT CHARACTERISTICS (N=12) SAFETY: FCA Cohorts (N=6) Median age: 30 (20-61) • 0 dose limiting toxicity WHO classification: • 0 ICANS (immune effector cell associated • B-ALL with recurrent genetic abnormalities: neurotoxicity) 7 (5%)

  16. Slide 16: UCART22 Expansion Associated with Encouraging Anti-leukemic Activity

    UCART22 Expansion Associated with Encouraging Anti-leukemic Activity EFFICACY: FCA Cohorts (N=6) § Host lymphocytes on average remained suppressed § UCART22 Expansion was observed and was associated with anti-leukemic activity § 2/6 patients achieved blast reductions to < 5% by day 28 § 1 pt in DL2

  17. Slide 17: UCARTCS1 – MELANI-01 Study Schema

    UCARTCS1 – MELANI-01 Study Schema Phase I, Open Label Dose-Escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCARTCS1, Administered in Patients with Relapsed or Refractory Multiple Myeloma Screening LD Treatment Period Follow-up Total N= up to 18 pts UCARTCS1 a

  18. Slide 18: Preliminary Data Validate CS1 as a Target for CAR-T in Multiple Myeloma

    Preliminary Data Validate CS1 as a Target for CAR-T in Multiple Myeloma D28: BM biopsy M protein MRD-Neg VGPR 4000 showed MRD- by Serum IgG 3000 FACS analysis M3: BM negative for Serum free lambda LC 2000 MM cells 1000 mg/dL 5 D90: IFE +ve 4 3 2 1 0 Screening D0 D14 D28 M2(D49) M3(D77) D90 Vector co

  19. Slide 19: UCART123 – AMELI-01 Trial Design

    UCART123 – AMELI-01 Trial Design Phase I, Open Label Dose-escalation And Dose-expansion Study To Evaluate The Safety, Expansion, Persistence And Clinical Activity Of UCART123 In Patients With Relapsed or Refractory Acute Myeloid Leukemia Determine MTD Dose Escalation and/or RP2D Dose Expansion Up to

  20. Slide 20: UCART20x22 – A Dual Allogeneic CAR-T for B-cell Malignancies

    UCART20x22 – A Dual Allogeneic CAR-T cells for B-cell Malignancies Why UCART20x22? • Strong alternative to CD19 (highly competitive/crowded) • CD22 and CD20 are validated targets in B-cell malignancies • Dual targeting designed for better killing & to prevent target escape • Strong in vitro and in v

  21. Slide 21: UCART20x22 – Efficient Activity in Vivo Against Multiple Target Combinations

    UCART20x22 – Efficient Activity in Vivo Against Multiple Target Combinations Single mouse carrying subcutaneous Efficient in vivo clearance of tumors expressing lymphoma tumors expressing different one or two antigens (CD20 and/or CD22) in a antigen combinations dose dependent manner, starting at lo

  22. Slide 22: Cellectis' UCART Platform Takeaways

    Cellectis’ UCART Platform Takeaways 170+ patients administered UCART derived from Cellectis’ technology 1. GvHD: TCRa KO results in safe, non-alloreactive UCART 2. Engraftment: CD52 KO + alemtuzumab provides a safe, effective & controllable therapeutic window 3. Persistence: Redosing feasible; encou

  23. Slide 23: Cellectis Organization

    CELLECTIS ORGANIZATION 23

  24. Slide 24: From UCART Discovery to Patients' Bedside

    From UCART Discovery to Patients’ Bedside ALPHA Study Paris Paris, France Raleigh, North Carolina New York, New York HQ, PD/AD, Starting Materials UCART – Clinical & Commercial Innovation, Clinical Development 55,000 sq ft. facility 82,000 sq ft. facility 25,000 sq ft. facility ü Process & analytica

  25. Slide 25: Cellectis 2022 Expected Milestones & Updates

    Cellectis 2022 Expected Milestones & Updates UCART22 UCART123 UCARTCS1 Enroll DL3 with FCA Enroll DL2 and DL2i with Enroll DL1 with FC preconditioning and start FCA preconditioning preconditioning dosing with products manufactured in-house UCART20x22 GMP FACILITIES PARTNERS File IND and initiate Pha

  26. Slide 26: Key Takeaways – Why Cellectis?

    Key Takeaways – Why Cellectis? Innovative Allogeneic CAR-T Breaking Paradigms with Life-Saving Therapies End-to-end In-house Manufacturing Owning Manufacturing is Owning the Product Best-In-Class Gene Editing Platform Safe, Powerful & Comprehensive Strong Partnerships Diversified Indications Leading

  27. Slide 27: Thank You

    THANK YOU Reach us at: investors@cellectis.com Cellectis Paris Cellectis New York Cellectis Raleigh 8, rue de la Croix Jarry 430 East 29th Street 2500 Sumner Boulevard 75013 Paris – France 10016 New York, NY – USA 27616 Raleigh, NC – USA

Cellectis — Investor Presentation (January 2022) on 6ix